Press release content from Business Wire. The AP news staff was not involved in its creation.
Apic Bio Announces FDA Clearance of IND Application for Lead Gene Therapy Candidate APB-102 for the Treatment of SOD1 ALS
April 21, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Apr 21, 2021
Apic Bio, Inc., an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for APB-102, the Company’s lead gene therapy candidate designed to treat SOD1 amyotrophic lateral sclerosis (ALS) - a common cause of familial ALS.